COVID-19 vaccines reduce hospitalization risk from Delta variant by at least 90 percent, U.K. studies find
Public health officials are worried about the Delta variant of the COVID-19 coronavirus, but two U.K. studies published Monday found that two doses of leading vaccines offer "very, very substantial" protection against the new, highly transmissible strain, Aziz Sheikh, director of the University of Edinburgh's Usher Institute and lead author of one of the two studies, tells The Wall Street Journal.
One analysis by Public Health England of more than 14,000 Delta infections found that two doses of the Pfizer/BioNTech vaccine reduced the risk of hospitalization by 96 percent, while a double dose of the Oxford-AstraZeneca vaccine lowered the risk by 92 percent. The second study, published as a letter in The Lancet by academics and public health experts in Scotland, found that two doses of either vaccine reduced hospitalization from the Delta variant by 70 percent and offered robust but slightly diminished protection against infection.
The Delta variant, first seen in India, is now the dominant strain in Britain, accounting for 90 percent of new cases. Compared with previous variants, the Delta mutation appears significantly more likely to infect people who have only received one dose of the two-shot vaccines. The U.K.'s initial vaccination strategy involved getting one jab into as many arms as possible before focusing on second doses. "We've got an opportunity to counter the threat of this Delta variant by encouraging uptake of both doses of the vaccine," Jim McMenamin, national incident director for COVID-19 at Public Health Scotland, told reporters Monday.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published